Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: A double blind randomized clinical trial

International Journal of Preventive Medicine

Volumn 4, Issue 5, 2013, Pages 531-537

  Shavakhi, Ahmad ^a   Minakari, Mohammad ^a   Firouzian, Hassan ^a   Assali, Raheleh ^b   Hekmatdoost, Azita ^c   Ferns, Gordon ^d  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NORTH KHORASAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KEELE UNIVERSITY   (United Kingdom)

Author keywords

Aminotransferase; Insulin resistance; Non alcoholic fatty liver disease; Nonalcoholic steatohepatitis; Probiotic; Randomized clinical trial

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; METFORMIN; PLACEBO; PROBIOTIC AGENT; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 84879600250     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Medina J, Fern'andez-Salazar JI, Garcia-Buey L, Moreno-Oteror. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004;27:2057-2066.
2. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 2004;8:501-519.
3. Preiss D, Sattar N. Non-alcoholic fatty liver disease: An overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci 2008;115:141-150.
4. Neuschwander-Tetri B, Caldwell S. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-1219.
5. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008;134:1682-1698.
6. Heidari K, Sajjadi SA, Hadian R, Hadi S, Hosseinkhani R, Amini S, et al. Establishment of health clinics as mass screening and referral systems for chronic non-communicable diseases in primary health care. Int J Prev Med 2012;3:173-180.
7. Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, et al. World gastroenterology organisation global guidelines: Probiotics and prebiotics October 2011. J Clin Gastroenterol 2012;46:468-481.
8. Lata J, Jurankova J, Kopacova M, Vitek P. Probiotics in hepatology. World J Gastroenterol 2011;17:2890-2896.
9. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor á in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206-211.
10. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:691-701.
11. Shanab AA, Scully P, Crosbie O, Buckley M, O'Mahony L, Shanahan F, et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: Association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011;56:1524-1534.
12. Gratz SW, Mykkanen H, El-Nezami HS. Probiotics and gut health: A special focus on liver diseases. World J Gastroenterol 2010;16:403-410.
13. Karahan N, Isler M, Koyu A, Karahan AG, Basyigit Kiliç G, Ciris, IM, et al. Effects of probiotics on methionine cholinedeficient diet-induced steatohepatitis in rats. Turk J Gastroenterol 2012;23:110-121.
14. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and Antibodies to TNF Inhibit Inflammatory Activity and Improve Nonalcoholic Fatty Liver Disease. Hepatology 2003;37:343-350.
15. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, et al. Beneficial effects of a probiotic VS.L#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005;39:540-543.
16. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011;15:1090-1095.
17. Wong VW, Wong GL, Tse CH, Chan HL. Treatment of nonalcoholic steatohepatitis with probiotics-A proof-of-concept study with serial gut microbiota analysis by ultra-deep sequencing. The International Liver Congress 2011. Berlin, Germany; March 30, 2011.
18. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 2011;305:1659-1668.
19. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-1090.
20. Haukeland JW, Konopski Z, Eggesbø HB, von Volkmann HL, Raschpichler G, Bjøro K, et al. Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial. Scand J Gastroenterol 2009;44:853-860.
21. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic Steatohepatitis. Gastroenterology 2008;135:1176-1184.
22. Rogha M, Najafi N, Azari A, Kaji M, Pourmoghad Z, Rezaee M. Non-alcoholic Steatohepatitis in a sample of Iranian adult population: Age is a Risk Factor. Int J Prev Med 2011;2:24-27.